Nervous System News and Research

Latest Nervous System News and Research

KemPharm to formulate and develop KP106 as oral film dosage for ADHD treatment

KemPharm, Inc. today announced that KP106, its clinical candidate for Attention Deficit/Hyperactivity Disorder, will be formulated and developed in an oral film dosage form pursuant to an exclusive collaboration agreement with MonoSol Rx relating to the development, commercialization and manufacture of KP106.

26 Apr 2011

MonoSol Rx, KemPharm enter development and commercialization partnership for ADHD prodrug

MonoSol Rx, LLC, the developer of PharmFilm® drug delivery technology, today announced that the Company has entered into a development and commercialization partnership with KemPharm, a biopharmaceutical company focused on the discovery and development of new, safer therapies for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), pain, and cardiovascular disease.

25 Apr 2011

Rwanda, QIAGEN and Merck launch comprehensive national cervical cancer prevention program

The Government of Rwanda, together with QIAGEN N.V. and Merck, known as MSD outside the United States and Canada, today announced the launch, in Kigali, Rwanda, of a comprehensive national cervical cancer prevention program that includes vaccination with GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] for appropriate girls 12 to 15 years of age and modern molecular diagnostic screening for women between the ages of 35 and 45.

From QIAGEN Manchester Limited 25 Apr 2011

XenoPort files SPA with FDA for arbaclofen placarbil Phase 3 trial in multiple sclerosis

XenoPort, Inc. announced today that it had reached agreement with the U.S. Food and Drug Administration on a Special Protocol Assessment for a pivotal Phase 3 clinical trial of arbaclofen placarbil, previously known as XP19986, as a potential treatment of spasticity in multiple sclerosis patients.

25 Apr 2011

GM-CSF appears to be key culprit in multiple sclerosis onset

Reporting in Nature Immunology, Jefferson neuroscientists have identified a driving force behind autoimmune diseases such as multiple sclerosis, and suggest that blocking this cell-signaling molecule is the first step in developing new treatments to eradicate these diseases.

25 Apr 2011

'Iceman' influences autonomic nervous system and immune response

At the Radboud University Nijmegen Medical Centre, professor of experimental intensive care medicine dr. Peter Pickkers and his team have performed research on "Iceman" Wim Hof. Hof claims that he can influence his autonomic nervous system and immune response through concentration and meditation.

22 Apr 2011

Organophosphates exposure during pregnancy may impair child cognitive development

Researchers at Mount Sinai School of Medicine have found that exposure during pregnancy to a family of pesticides called organophosphates may impair child cognitive development. The findings are published online in Environmental Health Perspectives.

22 Apr 2011

Marinus initiates ganaxolone Phase 2 trial in posttraumatic stress disorder

Marinus Pharmaceuticals, Inc., the leader in the development of neurosteroids for central nervous system disorders, today announced commencement of a proof-of-concept clinical trial of its lead candidate ganaxolone for the treatment of posttraumatic stress disorder.

22 Apr 2011

Opinions: Fight against malaria; small, medium businesses in developing countries; BP oil spill health implications

Despite progress over the past decade in the global fight against malaria, significant challenges remain, Awa Marie Coll-Seck, executive director of the Roll Back Malaria Partnership and former health minister of Senegal, writes in a Modern Ghana opinion piece ahead of World Malaria Day.

22 Apr 2011

Study finds ACE inhibitors linked to increased risk of recurrence in women who have had breast cancer

ACE inhibitors, commonly used to control high blood pressure and heart failure in women, may be associated with an increased risk of recurrence in women who have had breast cancer, according to a study by researchers at UCLA's Jonsson Comprehensive Cancer Center.

21 Apr 2011

Neurelis completes dosing in intranasal diazepam formulation study

Neurelis, Inc. today announced the completion of subject dosing in a randomized crossover study assessing diazepam pharmacokinetics and bioavailability after administration of two proprietary formulations of intranasal diazepam and intravenous injection.

21 Apr 2011

Neuralstem signs MoU with BaYi Brain Hospital for ischemic stroke program in China

Neuralstem, Inc. (NYSE Amex: CUR) announced it has signed a Memorandum of Understanding with BaYi Brain Hospital in Beijing, China.

21 Apr 2011

Amgen, UCB report positive results from AMG 785/CDP7851 comparative Phase 2 study for postmenopausal osteoporosis

Amgen and UCB announced today positive top-line results from their Phase 2 clinical study comparing sclerostin-antibody AMG 785/CDP7851 to placebo in postmenopausal women with low bone mineral density (BMD) for the treatment of postmenopausal osteoporosis (PMO).

21 Apr 2011

Blocking abnormal movement of mutated human FUS gene also blocks ALS process

In the first animal model of Amyotrophic Lateral Sclerosis (ALS), developed by Dr. Udai Pandey, Assistant Professor of Genetics at LSU Health Sciences Center New Orleans, Dr. Pandey's lab has found in fruit flies that blocking the abnormal movement of a protein made by a mutated gene called FUS also blocks the disease process.

20 Apr 2011

Adeona, TG United enter commercial-scale manufacturing agreement for reaZin

Adeona Pharmaceuticals, Inc., a developer of innovative medicines for serious central nervous system diseases, announced today that it has executed an agreement with TG United, Inc. of Brooksville, Florida, to provide commercial-scale manufacturing capabilities for reaZin. Adeona is developing reaZin, its product candidate for the dietary management of Alzheimer's disease and mild cognitive impairment, as a prescription medical food.

20 Apr 2011

Forest acquires worldwide rights to novel antiarrhythmic agent azimilide

Forest Laboratories, Inc. today announced that its wholly-owned subsidiary Forest Laboratories Holdings Limited and Blue Ash Therapeutics, LLC have entered into an asset purchase agreement, pursuant to which Forest has acquired worldwide rights to azimilide, a novel antiarrhythmic agent originally developed by Procter & Gamble Pharmaceuticals.

20 Apr 2011

Acorda receives patent for AMPYRA tablets to improve walking in MS patients

Acorda Therapeutics, Inc. today announced that the United States Patent and Trademark Office has allowed U.S. Patent Application No. 11/010,828 entitled "Sustained Release Aminopyridine Composition."

20 Apr 2011

Positive results from first human masitinib phase 2 study in Alzheimer's disease published in peer-reviewed journal

AB Science SA, a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), announces the publication of results from the first human phase 2 study of masitinib carried-out in the treatment of Alzheimer's disease.

20 Apr 2011

Treatment commences in NeuroVive-HCL's 1,000 patient European cardioprotection trial

NeuroVive Pharmaceutical and Hospices Civils de Lyon (HCL) today announced the enrollment and treatment of the first patient in the European multicenter trial of myocardial infarction (the CIRCUS study). NeuroVive's advanced CicloMulsion(TM) cremophor-free IV cyclosporine formulation is used in this study of 1,000 patients undergoing percutaneous coronary intervention (PCI) for acute myocardial infarction to examine cyclosporine's ability to protect cardiac tissue.

20 Apr 2011

Forest Labs fourth quarter net sales increase 9.7% to $1,091.9 million

Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, announced that reported earnings per share equaled $1.12 in the fourth quarter of fiscal 2011.

19 Apr 2011

Nervous System News and Research

Latest Nervous System News and Research

KemPharm to formulate and develop KP106 as oral film dosage for ADHD treatment

MonoSol Rx, KemPharm enter development and commercialization partnership for ADHD prodrug

Rwanda, QIAGEN and Merck launch comprehensive national cervical cancer prevention program

XenoPort files SPA with FDA for arbaclofen placarbil Phase 3 trial in multiple sclerosis

GM-CSF appears to be key culprit in multiple sclerosis onset

'Iceman' influences autonomic nervous system and immune response

Organophosphates exposure during pregnancy may impair child cognitive development

Marinus initiates ganaxolone Phase 2 trial in posttraumatic stress disorder

Opinions: Fight against malaria; small, medium businesses in developing countries; BP oil spill health implications

Study finds ACE inhibitors linked to increased risk of recurrence in women who have had breast cancer

Neurelis completes dosing in intranasal diazepam formulation study

Neuralstem signs MoU with BaYi Brain Hospital for ischemic stroke program in China

Amgen, UCB report positive results from AMG 785/CDP7851 comparative Phase 2 study for postmenopausal osteoporosis

Blocking abnormal movement of mutated human FUS gene also blocks ALS process

Adeona, TG United enter commercial-scale manufacturing agreement for reaZin

Forest acquires worldwide rights to novel antiarrhythmic agent azimilide

Acorda receives patent for AMPYRA tablets to improve walking in MS patients

Positive results from first human masitinib phase 2 study in Alzheimer's disease published in peer-reviewed journal

Treatment commences in NeuroVive-HCL's 1,000 patient European cardioprotection trial

Forest Labs fourth quarter net sales increase 9.7% to $1,091.9 million

Everything you need to know about epilepsy eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Nervous System News and Research

Latest Nervous System News and Research

Everything you need to know about epilepsy eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in